Scarica l'app Stockscreener
1.81
5.73%
-0.11
Dopo l'orario di chiusura:
1.82
0.01
+0.55%
Precedente Chiudi:
$1.92
Aprire:
$1.9
Volume 24 ore:
236.29K
Relative Volume:
1.36
Capitalizzazione di mercato:
$24.40M
Reddito:
-
Utile/perdita netta:
$-30.16M
Rapporto P/E:
-5.3235
EPS:
-0.34
Flusso di cassa netto:
$-39.49M
1 W Prestazione:
-10.84%
1M Prestazione:
-16.97%
6M Prestazione:
-39.26%
1 anno Prestazione:
-53.47%
Intervallo 1D:
$1.8001
$1.9592
Intervallo di 1 settimana:
$1.8001
$2.06
Portata 52W:
$1.8001
$9.19
Dare Bioscience Inc Stock (DARE) Company Profile
Nome
Dare Bioscience Inc
Settore
Industria
Telefono
858-926-7655
Indirizzo
3655 NOBEL DRIVE, SAN DIEGO, CA
Confronta DARE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
1.81 | 25.88M | 0 | -30.16M | -39.49M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dare Bioscience Inc Borsa (DARE) Ultime notizie
Dare Bioscience to Receive Up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment - MarketScreener
Will Daré Bioscience Inc. stock sustain high P E ratiosPortfolio Value Summary & Weekly Market Pulse Updates - newser.com
Daré Bioscience receives $4 million grant installment for contraceptive device By Investing.com - Investing.com Nigeria
Daré Bioscience Receives $4 Million Non-Dilutive Grant - GlobeNewswire
Law Custodial Inc. Files Schedule 13G Showing 1.41M DARE Shares - Stock Titan
Dare Bioscience (DARE) Secures $4M for Long-Acting Contraceptive Development - GuruFocus
Daré Bioscience receives $4 million grant installment for contraceptive device - Investing.com India
Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic - GlobeNewswire
$41.8M Received to Date — Daré Bioscience Advances DARE-IDDS Contraception Program, Seeks Partners - Stock Titan
Daré Bioscience enters into $15M stock purchase agreement - MSN
Dare Bioscience risks Nasdaq delisting over market value - MSN
DARE Secures Gates Foundation Funding for Preeclampsia Projects - GuruFocus
Daré Bioscience, Inc. Secures $499,000 Grant from Gates Foundation to Address Preeclampsia in Women's Health - Quiver Quantitative
Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research - GlobeNewswire
76,000 Maternal Deaths Annually: Daré Bioscience Receives Gates Grant to Combat Preeclampsia Crisis - Stock Titan
Dare Bioscience (NASDAQ:DARE) Shares Pass Below 200 Day Moving Average – What’s Next? - Defense World
Daré Bioscience targets Q4 2025 launch for DARE to PLAY Sildenafil cream while advancing dual-path strategy - MSN
Dare Bioscience files to sell 2.75M shares of common stocks by selling shareholders - MSN
What’s the recovery path for long term holders of Daré Bioscience Inc.Inflation Watch & Low Drawdown Investment Ideas - newser.com
Using Python tools to backtest Daré Bioscience Inc. strategies2025 Price Action Summary & Comprehensive Market Scan Insights - Newser
Maxim upgrades Daré Bioscience on extended cash runway, commercial launch - TradingView
Maxim Group upgrades Dare Bioscience stock to Buy on funding boost - Investing.com Canada
Dare Bioscience (DARE) Upgraded to Buy by Maxim Group | DARE Sto - GuruFocus
Dare Bioscience shares rise 4.37% premarket after Maxim upgraded to Buy from Hold. - AInvest
Dare Bioscience: Maxim Group upgrades Buy from Hold, PT $8. - AInvest
Maxim Upgrades Dare Bioscience to Buy From Hold, Price Target is $8 - MarketScreener
This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Daré Bioscience Engages Market with New Presentation - TipRanks
Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2025 Earnings Call Transcript - MSN
Pattern recognition hints at Daré Bioscience Inc. upsideQuarterly Trade Review & Long-Term Safe Investment Ideas - Newser
Brookline Capital Markets Sticks to Their Buy Rating for Daré Bioscience (DARE) - The Globe and Mail
Dolliver Maintains Buy Rating on Daré Bioscience with $11 Price Target - AInvest
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates - MSN
Dare Bioscience stock price target lowered to $11 at Brookline Capital - Investing.com Canada
Daré Bioscience's Strategic Growth and Market Expansion Ahead of Sildenafil Cream Launch - AInvest
Daré Bioscience: Strategic Growth and Market Expansion with Upcoming Sildenafil Cream Launch - TipRanks
Dare Bioscience shares fall 3.55% after-hours following Q2 2025 earnings call. - AInvest
Dare Bioscience 2025 Q2 Earnings Net Loss Widens Sharply - AInvest
Dare Bioscience 2025 Q2 Earnings Sharp Net Loss Deteriorates 131% - AInvest
Dare Bioscience Inc (DARE) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
Daré Bioscience Announces Q2 2025 Financial Results - TipRanks
Daré Bioscience Q2 2025 Earnings Call: Financial Results and Business Update - AInvest
Daré Bioscience's Q2 2025: Diverging Paths in Marketing, Financial Health, and R&D Investment - AInvest
Daré Bioscience's Q2 2025 Earnings: A Strategic Inflection Point in Women's Health Innovation - AInvest
Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Earnings call transcript: Dare Bioscience Q2 2025 reports cash boost, product updates - Investing.com Canada
Transcript : Daré Bioscience, Inc., Q2 2025 Earnings Call, Aug 14, 2025 - MarketScreener
Daré Bioscience Posts Narrower Q2 Loss - The Motley Fool
Dare Bioscience Inc Azioni (DARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):